openPR Logo
Press release

Carcinoid Tumor Market Size, Epidemiology, Leading Companies, Drugs, Pipeline Therapies and Competitive Analysis by DelveInsight

04-13-2022 07:58 AM CET | Health & Medicine

Press release from: DelveInsight Business Research

Carcinoid Tumor Market

Carcinoid Tumor Market

DelveInsight's "Carcinoid Tumor Market Insights, Epidemiology, and Market Forecast-2030" report delivers an in-depth understanding of the Carcinoid Tumor , historical and forecasted epidemiology as well as the Carcinoid Tumor market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Some key facts of Carcinoid Tumor Market Report:

1. Literature studies suggest that women are more likely to develop carcinoid tumors than men.

2. The incidence of Neuroendocrine tumors was approximately 2/100,000 with a female preponderance under the age of 50 years due to appendiceal location. The main primary sites were the gastrointestinal tract (62-67%) and the lung (22-27%). Presentation with metastatic disease accounts for 12-22%.

3. According to the American Society of Clinical Oncology (ASCO) in 2016, approximately 8,000 adults in the US were diagnosed with a carcinoid tumor in their GI tract.

4. It is estimated that each year approximately 4,000 adults in the United States diagnose with the carcinoid tumor in their lung.

5. Expected launch of Nivolumab + Cabozantinib, Pembrolizumab and other emerging drugs for treating CT shall fuel the growth of the market

Find a sample copy of the Carcinoid Tumor Market report - https://www.delveinsight.com/report-store/carcinoid-tumor-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Scope of the Carcinoid Tumor Report:

• The Carcinoid Tumor report covers the descriptive overview of Carcinoid Tumor , explaining its causes, signs and symptoms, pathophysiology, diagnosis and currently available therapies
• Comprehensive insight has been provided into the Carcinoid Tumor epidemiology and treatment in the 7MM
• Additionally, an all-inclusive account of both the current and emerging therapies for Carcinoid Tumor are provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
• A detailed review of Carcinoid Tumor market; historical and forecasted is included in the report, covering drug outreach in the 7MM
• The Carcinoid Tumor report provides an edge while developing business strategies, by understanding trends shaping and driving the global Carcinoid Tumor market

Request a sample and discover more about the scope of the report offerings: https://www.delveinsight.com/report-store/carcinoid-tumor-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Carcinoid Tumors are a type of slow-growing cancers that can arise in several places throughout the body and are characterized by the production of an excess of hormone-like substances, such as serotonin, bradykinin, histamine, and prostaglandins which leads to the other associated complications. These tumors, are the subset of neuroendocrine tumors and usually begin in the digestive tract (stomach, appendix, small intestine, colon) or in the lungs. On the basis of their location of origin, these tumors are categorized into three areas as Foregut: The foregut includes the lungs and the stomach; Midgut: comprised of the small intestine, appendix, and the beginning of the large bowel (colon), and Hindgut: composed of the end of the large bowel, and the organs of the genitourinary tract (ovaries, testes).

For further information on the Carcinoid Tumor current pipeline therapeutics, reach out: https://www.delveinsight.com/report-store/carcinoid-tumor-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

In the terms of their reported occurrence, CT most commonly develops in the gastrointestinal tract. However, they can also occur in other parts of the body such as the lungs, ovaries, or testicles. Based on the location and size of the tumor, CT usually presents with the subset of the symptoms such as cutaneous flushing, itching, and palpitation, edema, salivation, upper body erythema, chronic diarrhea, malabsorption, and breathing difficulties, etc. Till now, the associated causes of CT remains largely unknown, however common risk factors includes getting affected with disorders, such as multiple endocrine neoplasia, pernicious anemia, or Zollinger- Ellison syndrome, etc.

Find out more about the disease and recently developing strategies: https://www.delveinsight.com/report-store/carcinoid-tumor-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

The Key players involved in the Carcinoid Tumor market are:
1. Amgen Inc.
2. Novartis AG
3. Exelixis, Inc.
4. AVEO Pharmaceuticals, Inc.
5. Boehringer Ingelheim GmbH
6. Aegis Therapeutics, LLC
7. Chiasma, Inc.
8. Delcath Systems Inc.
9. CRINETICS PHARMACEUTICALS
And Many Others.

Dive deep into rich insights for emerging drugs and pipeline assessment, visit: https://www.delveinsight.com/sample-request/carcinoid-tumor-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Table of Contents:
1. Key Insights
2. Executive Summary of Carcinoid Tumor
3. Competitive Intelligence Analysis for Carcinoid Tumor
4. Carcinoid Tumor : Market Overview at a Glance
5. Carcinoid Tumor : Disease Background and Overview
6. Patient Journey
7. Carcinoid Tumor Epidemiology and Patient Population
8. Treatment Algorithm, Current Treatment, and Medical Practices
9. Carcinoid Tumor Unmet Needs
10. Key Endpoints of Carcinoid Tumor Treatment
11. Marketed Products
List to be continued in report
12. Emerging Therapies
List to be continued in report
13. Carcinoid Tumor : Seven Major Market Analysis
14. Attribute analysis
15. 7MM: Market Outlook
16. Access and Reimbursement Overview of Carcinoid Tumor
17. KOL Views
18. Carcinoid Tumor Market Drivers
19. Carcinoid Tumor Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
23. About DelveInsight

Get the TOC of the Carcinoid Tumor Market report here:
https://www.delveinsight.com/sample-request/carcinoid-tumor-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

About DelveInsight
DelveInsight is a premier Business Consulting and Market Research firm focused exclusively on the life science segment. With a wide array of smart end-to-end solutions, the firm helps the global Pharmaceutical and Bio-Tech companies formulate prudent business decisions.

Media Contact
Company Name: DelveInsight Business Research
Contact Person: Ankit Nigam
Email: info@delveinsight.com
Phone: +19193216187
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/

428, D21 Corporate Park, Sector-21, Dwarka, New Delhi-110077, India

DelveInsight is a leading Life Science market research and business consulting company recognised for its off-the-shelf syndicated market research reports as well as customised solutions to firms in the healthcare sector.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Carcinoid Tumor Market Size, Epidemiology, Leading Companies, Drugs, Pipeline Therapies and Competitive Analysis by DelveInsight here

News-ID: 2601675 • Views:

More Releases from DelveInsight Business Research

Pharma Asset Management Success Story: Strategic In-Licensing in the Atrial Fibrillation Space by DelveInsight
Pharma Asset Management Success Story: Strategic In-Licensing in the Atrial Fibr …
DelveInsight, a leading business consulting and market research firm, is pleased to announce the successful completion of an Asset Prioritization project that enabled a mid-sized pharmaceutical client to identify, evaluate, and secure a high-value therapeutic asset for in-licensing in the Atrial Fibrillation (AF) space. The case study highlights how evidence-based insights, structured methodologies, and multi-layered evaluations supported the client in achieving its long-term strategic growth goals. Objective of the Case Study The
Myopia Clinical Trials Outlook 2025: Competitive Landscape, Regulatory Milestones, Therapies in Development, Mechanisms of Action, and Routes of Administration - By DelveInsight
Myopia Clinical Trials Outlook 2025: Competitive Landscape, Regulatory Milestone …
(Albany, USA) - DelveInsight's newly released report, "Myopia Pipeline Insight 2025," delivers an in-depth assessment of the clinical trial landscape, regulatory progress, and therapeutic development trends shaping the Myopia therapeutics market. The analysis highlights ongoing clinical advancements, pipeline opportunities, and the potential impact of emerging therapies on patient care and market dynamics. According to DelveInsight's evaluation, the Myopia pipeline remains highly active, with 8+ pharmaceutical and biotechnology companies investigating more than
Global Biopsy Devices Market to Reach USD 10.81 Billion by 2032, Driven by Rising Cancer Burden and Technological Advancements, states DelveInsight
Global Biopsy Devices Market to Reach USD 10.81 Billion by 2032, Driven by Risin …
The global biopsy devices market is poised for significant growth, with market size projected to increase from USD 5,813.16 million in 2024 to USD 10,812.77 million by 2032, expanding at a CAGR of 8.09% during 2025-2032. The robust expansion is being driven by the growing incidence of cancers, rising demand for minimally invasive diagnostic procedures, and rapid advancements in biopsy technologies. Biopsy devices play a crucial role in disease diagnosis by
Global General Surgery Devices Market to Reach USD 35.4 Billion by 2032, Driven by Rising Surgical Procedures, Technological Advancements, and Growing Adoption of Minimally Invasive Techniques, States DelveInsight
Global General Surgery Devices Market to Reach USD 35.4 Billion by 2032, Driven …
According to the latest market analysis, the global general surgery devices market is set for robust growth, increasing from USD 21,786.29 million in 2024 to USD 35,399.63 million by 2032, expanding at a CAGR of 6.34% during 2025-2032. This growth reflects a surge in surgical procedures, continuous technological advancements, and rising demand for minimally invasive and robotic-assisted surgical techniques across healthcare systems worldwide. DelveInsight's General Surgery Devices Market Report 2032 provides

All 5 Releases


More Releases for Carcinoid

Carcinoid Syndrome Market is expected to reach USD 3.5 billion by 2034
Carcinoid syndrome is a rare but serious condition that develops when neuroendocrine tumors (NETs) produce excess hormones such as serotonin. Patients often experience flushing, diarrhea, abdominal cramping, and heart complications. While carcinoid syndrome is relatively uncommon compared to other oncological conditions, its impact on patient quality of life and long-term survival is profound. Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/71185 With neuroendocrine tumor incidence steadily increasing worldwide, the need
Global Carcinoid Syndrome Management Market Will Generate Record Revenue by 2028
This Carcinoid Syndrome Management market report contains a wealth of information about future breakthroughs and innovations. It goes on to discuss the impact of these developments on the market's overall economic growth. This Carcinoid Syndrome Management market report is also beneficial to industries in understanding the essential issues and opportunities that manufacturers face in the workplace. The impact of the COVID-19 pandemic on the market is predicted to be detrimental.
Carcinoid Syndrome Diarrhea Treatment Market - Increasing prevalence of rare car …
Carcinoid Syndrome Diarrhea Treatment Market report is a exploration database spread across colorful runners with multiple tables and numbers in it. The exploration covers a precious source of perceptive information for business strategists. Carcinoid Syndrome Diarrhea Treatment Industry provides the overview with growth analysis and literal & futuristic cost, profit, demand and force data (as applicable). The exploration judges give an elegant description of the value chain and its distributor
Carcinoid Syndrome Diarrhea Treatment Market Size, Status and Forecast To
Carcinoid Syndrome Diarrhea Treatment Market The Global Carcinoid Syndrome Diarrhea Treatment Market research report provides a unique methodology for evaluating the market insights, highlighting opportunities and supporting strategic and tactical decision-making. This report recognizes the requirement of a rapidly-evolving and competitive environment, up-to-date marketing information is essential to monitor performance and make critical decisions for growth and profitability. It provides information on the latest trends and developments and focuses on innovations
Carcinoid Syndrome Management Market to Witness Exponential Growth by 2027
Carcinoid syndrome comprises of signs and symptoms such as flushing of the face, debilitating diarrhea, asthma caused due to vasoconstriction, intestinal bleeding, fast heartbeat, shortness of breath, sweating, unexplained weight gain etc. which are developed secondary to carcinoid tumor. The term ‘carcinoid crisis’ is used when all the symptoms of carcinoid syndrome show at a time. Carcinoid tumors arise out of neuroendocrine cells which are present all over the human
Carcinoid Syndrome Diarrhea Treatment Market Size, Status and Forecast 2017 – …
Carcinoid syndrome is a group of symptoms that can occur in patients suffering from carcinoid tumors which also called as metastatic neuroendocrine tumors. Carcinoid tumors are rare and these are slow growing tumors. Most of the tumors occur in gastrointestinal tract. According to FDA, carcinoid syndrome occurs in less than 10 percent of people suffering from carcinoid tumors, mostly after the tumor has spread to the liver. This syndrome causes